This drug developed by AI for lungs disease enters human clinical trials
The use case scenario of artificial intelligence is growing faster than expected. AI is being used in several key industries to make things more efficient and effective. The latest industry to become onboard on AI-based systems is the pharma industry and recently a drug for curing liver disease known as Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring in the lungs, has been discovered and designed using artificial intelligence has entered into human clinical trials.
Clinical trial for INS018_55 has started
Insilico Medicine, a Hong Kong-based biotechnology company has released a statement announcing that the Phase II trial on the oral dosage of INS018_55 is being carried out over 12 weeks in China. The company also mentions that they are planning to expand this trial to 60 people in the US and China.
The company also aims to study the drug with more people, if the trial becomes successful.
“With demonstrated potential against both fibrosis and inflammation, INS018_055 could offer another option for patients worldwide,” said Feng Ren, co-CEO and Chief Scientific Officer of Insilico Medicine, in the statement.
On this, Alex Zhavoronkov, the founder and co-CEO of Insilico Medicine said that the Phase II trials of this drug that have been discovered and designed by AI represent the true validation of their generative AI platform. And, they will explore the efficacy for patients of this new AI-created drug.
Insilico Medicine started working on this drug in 2020
CNBC reported that the company started the development process back in 2020 with the idea of “moonshot” medicine to overcome the challenges of current treatments which mainly try to slow down the progression and also have several side effects.
Company has two more drugs developed using AI
Zhavoronkov also mentioned in the statement that the company has two more drugs that have been developed with the help of AI and are in the clinical stage. This includes the Covid-19 drug and the other one is a cancer drug. The former is in phase one trial, while the latter is a USP1 inhibitor for the treatment of solid tumours and has received FDA approval to begin the clinical trials.
FacebookTwitterLinkedin
end of article
The use case scenario of artificial intelligence is growing faster than expected. AI is being used in several key industries to make things more efficient and effective. The latest industry to become onboard on AI-based systems is the pharma industry and recently a drug for curing liver disease known as Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring in the lungs, has been discovered and designed using artificial intelligence has entered into human clinical trials.
Clinical trial for INS018_55 has started
Insilico Medicine, a Hong Kong-based biotechnology company has released a statement announcing that the Phase II trial on the oral dosage of INS018_55 is being carried out over 12 weeks in China. The company also mentions that they are planning to expand this trial to 60 people in the US and China.
The company also aims to study the drug with more people, if the trial becomes successful.
“With demonstrated potential against both fibrosis and inflammation, INS018_055 could offer another option for patients worldwide,” said Feng Ren, co-CEO and Chief Scientific Officer of Insilico Medicine, in the statement.
On this, Alex Zhavoronkov, the founder and co-CEO of Insilico Medicine said that the Phase II trials of this drug that have been discovered and designed by AI represent the true validation of their generative AI platform. And, they will explore the efficacy for patients of this new AI-created drug.
Insilico Medicine started working on this drug in 2020
CNBC reported that the company started the development process back in 2020 with the idea of “moonshot” medicine to overcome the challenges of current treatments which mainly try to slow down the progression and also have several side effects.
Company has two more drugs developed using AI
Zhavoronkov also mentioned in the statement that the company has two more drugs that have been developed with the help of AI and are in the clinical stage. This includes the Covid-19 drug and the other one is a cancer drug. The former is in phase one trial, while the latter is a USP1 inhibitor for the treatment of solid tumours and has received FDA approval to begin the clinical trials.
FacebookTwitterLinkedin
end of article
Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.